Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Capital Expenditures (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Capital Expenditures for 12 consecutive years, with $147000.0 as the latest value for Q1 2026.

  • For Q1 2026, Capital Expenditures changed N/A year-over-year to $147000.0; the TTM value through Mar 2026 reached -$428000.0, down 5294.17%, while the annual FY2025 figure was $11000.0, 10.31% up from the prior year.
  • Capital Expenditures hit $147000.0 in Q1 2026 for Crescent Biopharma, up from -$715000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $147000.0 in Q1 2026 and bottomed at -$715000.0 in Q4 2025.
  • Average Capital Expenditures over 5 years is -$26248.0, with a median of $7652.5 recorded in 2023.
  • Year-over-year, Capital Expenditures plummeted 99.96% in 2022 and then surged 80000.0% in 2023.
  • Crescent Biopharma's Capital Expenditures stood at $1.0 in 2022, then soared by 80000.0% to $801.0 in 2023, then soared by 828.71% to $7439.0 in 2024, then plummeted by 9711.51% to -$715000.0 in 2025, then skyrocketed by 120.56% to $147000.0 in 2026.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $147000.0, -$715000.0, and $140000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.